ASCO 2026 | SENOMAC: omitting axillary dissection improves outcomes in breast cancer

Jana de Boniface • 30 May 2026

ASCO 2026

Breast Cancer

SENOMAC

Jana de Boniface, MD, PhD, Karolinska Institutet, Stockholm, Sweden, presents overall survival and patient-reported outcomes from the SENOMAC trial (NCT02240472), a non-inferiority study evaluating omission of completion axillary lymph node dissection in patients with breast cancer and sentinel lymph node macrometastases. Results confirmed oncologic safety of omission, with comparable overall survival and breast cancer-specific survival, alongside significantly improved arm function and reduced arm morbidity, supporting omission as a safe standard approach in this population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.